129 Xenon MRI for Pulmonary Arterial Hypertension (PAH)

This study is looking at how a special type of MRI, called 129Xe MRI, can help doctors understand and track pulmonary arterial hypertension (PAH). PAH is a condition where blood pressure in the arteries of your lungs is too high. Researchers want to see if 129Xe MRI can show differences between common types of PAH and how well treatments are working over time. You might be able to join if you are 18-75 years old and have Idiopathic PAH or PAH linked to a connective tissue disease. The study will measure changes in your lung blood vessels using the 129Xe MRI over one year to see if it's a good way to monitor the disease.

Study design
This is an observational study involving 20 participants, split into two groups of 10 each, to compare different types of PAH.
What's involved
You would undergo 129Xe MRI/MRS scans at baseline, 3 months, 6 months, and 12 months. Standard medical assessments like labs, echocardiograms, and 6-minute walk tests will also be collected at these times.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 12 months to track changes in their condition.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06104228

129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)

Recruiting
PHASE2Ages 18–75InterventionalDiagnostic
Bastiaan Driehuys
~20 participants
Updated 2026-02-24 on ClinicalTrials.gov
What's tested:129Xe Hyperpolarized

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Pulmonary Vascular Remodeling
Measured over 1 year
Pulmonary Arterial Hypertension
Idiopathic Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension Associated With Connective Tissue Disease (Disorder)
Connective Tissue Diseases
1 sites across 1 states
North Carolina1
  • Fawaz Alenezi, MD · PRINCIPAL_INVESTIGATOR · Duke Univeristy

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age: 18-75 years
WHO functional class 2 or 3
Mean pulmonary artery pressures \> 20 mmHg
Pulmonary capillary wedge pressure ≤15 mmHg
Pulmonary vascular resistance \> 2 Wood Units (WU)
No other cause identified for PAH
Age: 18-75 years
WHO functional class (FC) 2 or 3
Mean pulmonary artery pressures \> 20 mmHg
Pulmonary capillary wedge pressure ≤15 mmHg
Pulmonary vascular resistance \> 2 WU
Diagnosis of connective tissue disease

Exclusion

PH other than Idiopathic PAH or PAH associated with CTD; any conditions that prevent the performance of 129Xe MRI scans will be excluded from the study.
  • Pulmonary Vascular Remodeling1 year

    The primary endpoint for this trial will be the change in defect + low percentage of RBC signal on hyperpolarized 129Xe MRI from baseline to 12 months